MIAMI—ONE Bio Corp. (OTC BB:ONBI) released its financial reports for the fourth quarter (4Q) and fiscal year (FY09), ended Dec. 31, 2009. Revenue hit $13.4 million in 4Q09, up 364 percent compared to the comparable 2008 quarter; operating income for 4Q09 was up 305 percent, hitting $3.99 million, while net income rose to $2.87 million, a 344 percent increase. For the fiscal year, ONE Bio posted revenue of $22.07 million, up 112 percent compared to $10.40 million in FY08. FY09 operating income was up 60 percent to $7.46 million, while net income was $5.38 million, a 61 percent increase.
The company further noted it completed the acquisition of its current operating businesses during 2009; however, only partial operating results from the acquired companies are reflected in the 2009 results. In looking at pro-forma financial results on a consolidated basis, FY09 pro-forma revenues were $39,354,753, compared to $34,839,128 for FY08, a 13 percent increase. Similarly, FY09 pro-forma operating income was $11,809,223 compared to FY08 figures of $10,469,878.
ONE Bio anticipates further improvements as the acquired companies are consolidated into the operation, product distribution expands, and further acquisitions are undertaken. Marius Silvasan, CEO, ONE Bio, stated, “Fourth quarter results reflect strong organic growth and the contribution of our recently completed acquisitions. Asia’s robust economic growth continues to fuel demand for our products. We are focused on highly sought-after organic products, herbal and chemical extracts and natural and health supplements. ONE Bio represents a viable alternative to U.S. investors seeking to invest in the growth of the Asia Pacific region but wanting a strong U.S. domestic management team coupled with Asian operational expertise. We have put in place a solid foundation for strong organic growth and continue to seek strategic acquisitions.”
